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The ‘worried-well’, insulin
resistance and metformin
therapy
To the Editor: Despite several recent local publications
1-3
pointing out the folly of measuring serum insulin levels, this
test is still being done on a regular basis by many practitioners.
There seems to be a total lack of understanding of the concept
of the ‘metabolic (insulin-resistant) syndrome’ among the
medical profession, which is resulting in a large number of
essentially healthy patients being told they are ‘insulin
resistant’ and being started on metformin therapy
inappropriately.
Over the past year we have been consulted by an increasing
number of such patients who are desperately concerned about
their ‘insulin resistance’.  Generally they are young or middle-
aged women, often with a history of depression or anxiety,
who are overweight.  Following a visit to a dietician or their
doctor, insulin levels are measured, found to be elevated and
the patients are started on metformin.  They then have serial
insulin levels measured and become fixated, often obsessed,
with the blood result, without any real understanding as to
what it means.  Frequently these vulnerable patients are keen
or even desperate to be offered a ‘diagnosis’ and in doing so
are made ‘worried-well’.
The relationships between cause and effect are
misunderstood and it seems to be forgotten that obesity,
inactivity and smoking cause, and are not caused by, elevated
insulin levels. Hyperinsulinaemia does not cause obesity, and
reducing insulin levels with pharmacotherapy does not cause
weight loss.
4
Just by looking at these patients one can often
surmise that their insulin levels will be raised, and the amount
of money being wasted and anxiety being engendered by
performing this unnecessary test is staggering.
The criteria for diagnosing the metabolic syndrome are well
defined
1
and do not include serum insulin levels. The diagnosis
is made on the basis of lipid profiles and the presence of
hypertension or dysglycaemia (fasting glucose with or without
a glucose tolerance test), and may include measurement of the
abdominal girth. The presence of nonspecific elevations in
hepatic enzymes may relate to possible non-alcoholic fatty
infiltration of the liver,
5
and may be another pointer to the
presence of the metabolic syndrome, although not considered
part of the diagnostic criteria.
The decision whether to use insulin sensitisers in patients
with impaired glucose tolerance is still being debated, but there
is certainly no evidence that these drugs will either help the
patient lose weight or prevent progression to diabetes in
individuals without dysglycaemia. The cornerstone of
treatment in these patients remains diet and exercise and the
treatment of any concurrent risk factors (hypertension,
dyslipidaemia), and no amount of metformin will change this.
The only recognised use of metformin outside the treatment of
the dysglycaemic patient would be for the treatment of
infertility in women with the polycystic ovarian syndrome.
The ‘commercialisation’ of the metabolic (insulin-resistant)
syndrome is creating a large number of ‘worried-well’ patients
who need little more than dietary advice and an exercise
programme, but are instead led to believe they have an esoteric
illness. The diagnosis of ‘insulin resistance’ has taken over from
the diagnosis of that other non-illness, reactive hypoglycaemia,
which was so prevalent a decade or so ago.
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High expenses for doctors
To the Editor: I wish to appeal to SAMA – I am sure on behalf
of my colleagues too – to help us decrease our expenditure.
Our membership fee for SAMA should be enough to cover
everything.  At present we have to pay for CPD points,
congresses, and revision courses, plus protection fees.
For a start, why should we pay a huge fee every 2 years to
update the Advanced Cardiac Life Support? Soon every
department will cash in unless we stop the rip-offs now. The
surgery, gynecology and medical departments, for example,
will state: ‘Knowledge of these subjects is poor after one year –
rewrite or lose your licence to practice’.
I cover work every day that is more important than the
ACLS, yet I have to redo it.  We shall strive to have the rule
forcing us to rewrite it every 2 years scrapped.
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